Topic: commercial manufacturing
In this webinar, AstraZeneca and Catalent Biologics experts will share a case study on a 30-day commercial launch plan for a product into new markets and why this approach was important for patients.
Merck & Co. won’t be able to fully meet global demand for HPV vaccine Gardasil until after 2023 when it completes two manufacturing plants.
Mylan recalls generic Xanax and Lonza expands cell therapy operations in Singapore while Glenmark is delivered an FDA warning letter.
Novartis' effort to cut up to $2 billion out of production units will play out next at its site in Cork, Ireland.
Chinese drugmaker BeiGene has opened the first phase of a $320 million facility where it intends to manufacture targeted cancer drugs.
With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.
Merck's expansion of Gardasil production in Virginia and now in North Carolina means $1.68 billion in investments and 525 new jobs.
Catalent is buying a site in Italy from Bristol-Myers Squibb that handles biologics along with old-school solid-dose production.
Tergus Pharma has snagged a new investor and that will help the dermatology specialist build a commercial manufacturing operation.
Dendreon has signaled faith in its struggling prostate drug Provenge by signing a 10-year lease extension for its California manufacturing facility.